Cryopreservation sits at a critical point in a CAR-T workflow because the cells must remain usable after freezing, storage, and thawing. A useful freezing medium therefore has to support more than a single immediate post-thaw reading: teams need evidence that cell viability, viable recovery, and engineered-cell characteristics remain measurable through recovery.
Kryogene Cell Freezing Media - CGT is a chemically defined, serum- and protein-free cryopreservation solution developed for next-generation cell therapies. It is engineered for CAR-T, NK, MSCs, iPSCs, and other advanced cell therapies, with a formulation designed to support cell viability and functional integrity through freezing, storage, and post-thaw recovery.
This article looks at the features that matter when selecting CGT cell freezing media for CAR-T workflows and uses CD19 CAR-T performance data to examine viability, CAR expression, cell density, and performance at both standard and concentrated freezing densities.
What Should CGT Cell Freezing Media Protect in a CAR-T Workflow?
For engineered T cells, post-thaw quality is multidimensional. The CAR-T data set evaluates several attributes together, which is more informative than looking at viability alone.
1. Post-Thaw Viability
Viability is the first checkpoint after thawing. Kryogene Cell Freezing Media - CGT is designed for high viability retention and consistent cell function and recovery post-thaw. In the CAR-T study, viability was assessed before freezing and again at 0h and 24h after thawing.
2. Viable Cell Recovery
A high percentage of viable cells is most useful when the workflow also recovers a practical number of cells. The comparative CAR-T assessment therefore includes viable cell recovery rate alongside viability change and CAR expression rate change at post-thaw time points.
3. CAR Expression
CAR expression is a key engineered-cell readout. The CD19 CAR-T study tracks CAR expression before freezing, immediately after thawing, and after 24h of recovery, allowing the freeze-thaw profile to be evaluated alongside viability and cell density.
What Defines a CGT-Ready Freezing Medium?
Chemically Defined, Serum- and Protein-Free Formulation
Kryogene Cell Freezing Media - CGT uses a chemically defined, serum- and protein-free formulation. For cell therapy development, a defined composition helps create a more controlled cryopreservation input while avoiding reliance on serum or protein components.
Cryoprotection Through Freeze-Thaw
The formulation is designed to minimize ice crystal formation and preserve cell integrity during freeze-thaw cycles. This cryoprotective function is paired with a ready-to-use format that eliminates preparation steps and supports reproducible handling.
Clinical-Grade Manufacturing and Batch Consistency
The medium is designed for clinical-grade cryopreservation and is manufactured under current Good Manufacturing Practice (cGMP) standards with USP-compliant raw materials. A closed, disposable manufacturing process is used to prevent cross-contamination between batches, with quality control supporting consistent performance across production lots.
CAR-T Cryopreservation Data: Three Batches, Two Cell Densities
Three batches of CD19 CAR-T cells were cryopreserved with Kryogene Cell Freezing Media - CGT and a competitive product. Each test group was frozen at two cell densities - 5 × 10^6 cells/mL and 2.5 × 10^7 cells/mL - and evaluated after thawing for cellular functional properties. The study follows viability, CAR expression, and cell density before freezing and at 0h and 24h post-thaw.
Standard-Density CAR-T Cryopreservation at 5 × 10^6 Cells/mL
At 5 × 10^6 cells/mL, the data show batch-level trajectories for viability, CAR expression, and cell density across the freeze-thaw window. Tracking the same measurements before freezing, immediately after thawing, and at 24h makes it possible to distinguish the immediate thaw response from the later recovery profile.
Figure 1. CD19 CAR-T viability and CAR expression at 5 × 10^6 cells/mL. Three CAR-T batches cryopreserved with Kryogene Cell Freezing Media - CGT and a competitive product were assessed before freezing and at 0h and 24h post-thaw.
Across the Kryogene groups shown, post-thaw viability remains high, while CAR expression is reassessed at 24h after the immediate 0h reading. Cell density was evaluated in parallel in the same study to provide an additional view of post-thaw recovery.
High-Density CAR-T Cryopreservation at 2.5 × 10^7 Cells/mL
The same CAR-T panel was also tested at 2.5 × 10^7 cells/mL, a five-fold higher cell concentration than 5 × 10^6 cells/mL. This high-density condition is especially useful for assessing whether a freezing medium can support concentrated cell banking without losing the key post-thaw readouts used to characterize the product.
Figure 2. High-density CD19 CAR-T viability and CAR expression at 2.5 × 10^7 cells/mL. Three batches cryopreserved with Kryogene Cell Freezing Media - CGT and a competitive product were assessed before freezing and at 0h and 24h post-thaw.
Even at the concentrated condition, the data show high post-thaw viability and recovery of CAR expression by 24h in the Kryogene groups. Together with the standard-density condition, the study provides CAR-T performance evidence across a five-fold density range.
How to Read the CAR-T Data as a Workflow
One practical way to use these results is to evaluate the cryopreservation step as a sequence rather than a single endpoint. The data provide a simple framework for method development and internal comparison:
• Before freezing: establish the baseline for viability, CAR expression, and cell density.
• Post-thaw 0h: capture the immediate effect of the freeze-thaw event, including viable cell recovery and expression changes.
• Post-thaw 24h: reassess viability and CAR expression after recovery rather than relying only on the immediate reading.
• Across densities: compare the same readouts at 5 × 10^6 cells/mL and 2.5 × 10^7 cells/mL to understand performance at standard and concentrated conditions.
This type of multi-parameter, multi-time-point assessment is particularly relevant to CAR-T workflows because it connects cell survival with the engineered-cell readout that researchers and process teams need to follow after thaw.
Kryogene Cell Freezing Media - CGT for CAR-T Workflows
Kryogene Cell Freezing Media - CGT combines a defined formulation with cell-therapy-focused manufacturing and CAR-T performance data. For teams developing or refining cryopreservation workflows, its main advantages are the combination of chemically defined composition, serum- and protein-free formulation, freeze-thaw cryoprotection, ready-to-use handling, and documented performance at both standard and high cell densities.
Key features and benefits:
• Optimized for cell therapies: engineered for CAR-T, NK, MSCs, iPSCs, and other advanced cell therapies.
• Chemically defined, serum- and protein-free cryopreservation solution.
• Superior cryoprotection: minimizes ice crystal formation to preserve cell integrity during freeze-thaw cycles.
• High viability retention: designed to support consistent cell function and recovery post-thaw.
• Clinical-grade manufacturing: cGMP standards with USP-compliant raw materials.
• Ready-to-use formulation: eliminates preparation steps and supports workflow efficiency.
• Batch-to-batch consistency: closed, disposable manufacturing process with rigorous quality control.
Product formats:
| Cat. No. | Product Description | Size | Store at |
| AR0008-100 | Cell Freezing Media - CGT | 100 mL/Bottle | 2-8 °C |
| AR0008-100B | Cell Freezing Media - CGT | 100 mL/Bag | 2-8 °C |
Kryogene products are presented under MileCell quality systems including ISO 9001, ISO 14001, and ISO 45001.
FAQ: CGT Cell Freezing Media for CAR-T Workflows
Is Kryogene Cell Freezing Media - CGT designed for CAR-T cells?
Yes. The medium is engineered for CAR-T, NK, MSCs, iPSCs, and other advanced cell therapies. CAR-T-specific performance testing was conducted with three batches of CD19 CAR-T cells.
What CAR-T attributes were measured after cryopreservation?
The study assessed post-thaw cell viability, viable cell recovery, CAR expression, and cell density. Viability, CAR expression, and cell density were followed before freezing and at 0h and 24h after thawing.
Has Kryogene Cell Freezing Media - CGT been tested at high cell density?
Yes. CD19 CAR-T cells were tested at both 5 × 10^6 cells/mL and 2.5 × 10^7 cells/mL. At the concentrated condition, the data show high post-thaw viability and recovery of CAR expression by 24h.
Is the formulation serum-free and protein-free?
Yes. Kryogene Cell Freezing Media - CGT is chemically defined, serum-free, and protein-free.
What manufacturing features support CGT use?
The product is designed for clinical-grade cryopreservation, manufactured under cGMP standards with USP-compliant raw materials, and produced using a closed, disposable manufacturing process for batch-to-batch consistency.
Conclusion
Selecting CGT cell freezing media for a CAR-T workflow requires evidence that connects post-thaw viability with viable cell recovery, CAR expression, and cell density. Kryogene Cell Freezing Media - CGT combines a chemically defined, serum- and protein-free formulation with cGMP manufacturing, USP-compliant raw materials, ready-to-use handling, and batch-consistent production. CD19 CAR-T data at 5 × 10^6 cells/mL and 2.5 × 10^7 cells/mL provide a practical basis for evaluating standard and concentrated cryopreservation conditions.
If you are evaluating a freezing medium for CAR-T development, high-density cell banking, or broader cell therapy research, explore Kryogene Cell Freezing Media - CGT and discuss your target cell density and post-thaw assessment plan with the MileCell team.
Contact: Info@milecell-bio.com | Website: www.milecell-bio.com
